Literature DB >> 21613812

Effects of antihypertensive treatments on incidence of diabetes: a case-control study.

M Monami1, A Ungar, C Lamanna, G Bardini, L Pala, I Dicembrini, C Marchi, M Vivarelli, S Zannoni, N Bartoli, N Marchionni, C M Rotella, E Mannucci.   

Abstract

AIMS: Aim of this case-control study is the assessment of the relationship between antihypertensive treatment and incidence of diabetes in an unselected cohort of subjects participating in a screening program for diabetes.
METHODS: A case-control study nested within a cohort of nondiabetic subjects with a mean follow-up of 27.7 ± 11.3 months was performed, comparing 40 cases of incident diabetes and 160 controls matched for age, sex, body mass index, fasting plasma glucose, 2-h post-load glycemia, smoking and alcohol abuse.
RESULTS: When considering antihypertensive treatment at enrolment, a lower proportion of cases was exposed to ACE-inhibitors/angiotensin receptor blockers (ACE-i/ARB) in comparison with controls. A non-significant trend toward a higher exposure to diuretics, which were mainly represented by thiazide diuretics, was observed in cases. In a multivariate analysis, including both ACE-i/ARB and diuretics, a protective effect of ACEi/ARB, and an increased risk with diuretics were observed. Similar results were obtained in alternative models, after adjusting for systolic and diastolic blood pressure at enrolment, diagnosis of hypertension, concurrent treatment with β-blockers or calcium-channel blockers, and number of antihypertensive medications.
CONCLUSIONS: Diuretics seem to be associated with a higher incidence of diabetes, whereas treatment with ACEi/ARB could have a protective effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613812     DOI: 10.3275/7750

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

1.  The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.

Authors:  M Middeke; W O Richter; P Schwandt; H Holzgreve
Journal:  Int J Clin Pharmacol Ther       Date:  1997-06       Impact factor: 1.366

2.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

3.  Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group.

Authors:  J Ostman; K Asplund; T Bystedt; B Dahlöf; S Jern; T Kjellström; H Lithell
Journal:  J Intern Med       Date:  1998-08       Impact factor: 8.989

4.  Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.

Authors:  Michael H Olsen; Eigil Fossum; Aud Høieggen; Kristian Wachtell; Elsa Hjerkinn; Shawna D Nesbitt; Ulrik B Andersen; Robert A Phillips; Cynthia L Gaboury; Hans Ibsen; Sverre E Kjeldsen; Stevo Julius
Journal:  J Hypertens       Date:  2005-04       Impact factor: 4.844

Review 5.  Guidelines for management of hypertension: report of the third working party of the British Hypertension Society.

Authors:  L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell
Journal:  J Hum Hypertens       Date:  1999-09       Impact factor: 3.012

6.  Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study.

Authors:  R Fernández; J G Puig; J C Rodríguez-Pérez; J Garrido; J Redon
Journal:  J Hum Hypertens       Date:  2001-12       Impact factor: 3.012

7.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

Authors:  Lars H Lindholm; Mats Persson; Petar Alaupovic; Bo Carlberg; Anders Svensson; Ola Samuelsson
Journal:  J Hypertens       Date:  2003-08       Impact factor: 4.844

Review 8.  The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Authors:  Nadia A Khan; Brenda Hemmelgarn; Robert J Herman; Simon W Rabkin; Finlay A McAlister; Chaim M Bell; Rhian M Touyz; Raj Padwal; Lawrence A Leiter; Jeff L Mahon; Michael D Hill; Pierre Larochelle; Ross D Feldman; Ernesto L Schiffrin; Norman R C Campbell; Malcolm O Arnold; Gordon Moe; Tavis S Campbell; Alain Milot; James A Stone; Charlotte Jones; Richard I Ogilvie; Pavel Hamet; George Fodor; George Carruthers; Kevin D Burns; Marcel Ruzicka; Jacques dechamplain; George Pylypchuk; Robert Petrella; Jean-Martin Boulanger; Luc Trudeau; Robert A Hegele; Vincent Woo; Phil McFarlane; Michel Vallée; Jonathan Howlett; Peter Katzmarzyk; Sheldon Tobe; Richard Z Lewanczuk
Journal:  Can J Cardiol       Date:  2008-06       Impact factor: 5.223

9.  Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance.

Authors:  E Mannucci; A Ognibene; I Sposato; M Brogi; G Gallori; G Bardini; F Cremasco; G Messeri; C M Rotella
Journal:  Acta Diabetol       Date:  2003-12       Impact factor: 4.280

10.  Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.

Authors:  Yoshiki Yui; Tetsuya Sumiyoshi; Kazuhisa Kodama; Atsushi Hirayama; Hiroshi Nonogi; Katsuo Kanmatsuse; Hideki Origasa; Osamu Iimura; Masao Ishii; Takao Saruta; Kikuo Arakawa; Saichi Hosoda; Chuichi Kawai
Journal:  Hypertens Res       Date:  2004-07       Impact factor: 3.872

View more
  1 in total

1.  Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study.

Authors:  Chia-Hsuin Chang; Yi-Cheng Chang; Li-Chiu Wu; Jou-Wei Lin; Lee-Ming Chuang; Mei-Shu Lai
Journal:  Cardiovasc Diabetol       Date:  2014-05-14       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.